April 14 (SeeNews) - Raiffeisen Capital & Investment (RCI) said it cut its recommendation on Romanian drug maker Biofarm [BSE:BIO] to reduce from buy and set a target price of 0.3 lei ($0.093/0.0671 euro) per share.